Key result
Male sex is linked to ~88% higher 90-day mortality versus female sex in HFmrEF.
Why the study?
Studies evaluating prognostic differences between men and women with HFmrEF are few, and evidence on sex differences in these patients is lacking.
Does male sex increase the risk of cardiovascular events and all-cause mortality in patients with HFmrEF compared to female sex?
Cohort (n=1,691)
No
Does male sex increase the risk of cardiovascular events and all-cause mortality in patients with HFmrEF compared to female sex?
Effect estimate: HR 1.88 (95% CI 1.03-3.46)
Absolute Event Rate: 5.7% vs 3%
p-value: p=0.041
Men with HFmrEF have a higher short-term (90-day) risk of all-cause mortality after hospital discharge compared to women, though this difference attenuates by 1 year.
May support closer post-discharge monitoring for men with HFmrEF; leaves open whether sex-specific strategies improve outcomes.
Clinical studies on heart failure with mildly reduced left ventricular ejection fraction (HFmrEF) have gradually increased. However, studies on the prognostic differences between men and women among patients with HFmrEF are few, and no evidence on sex differences in such patients exists. Therefore, we retrospectively assessed the data of patients with HFmrEF using propensity score-matched analysis (PSMA). A total of 1691 patients with HFmrEF were enrolled in the Outcome of Discharged HFmrEF Patients study (OUDI-HF study), which included 1095 men and 596 women. After propensity score matching, we compared the difference in cardiovascular (CV) events (cardiovascular death or heart failure readmission) and all-cause mortality at 90 days and 1 year after discharge between men and women using Kaplan-Meier analysis and Cox regression. After PSMA, men with HFmrEF were 2.2 times more likely to die at 90 days than women with HFmrEF [hazard ratio (HR) 1.88; 95% confidence interval (95% CI) 1.03-3.46; P = 0.041]. However, there was no difference in the 90-day CV events (HR 0.96; 95% CI 0.75-1.22; P = 0.718). Similarly, there was no difference in all-cause mortality (HR 1.16; 95% CI 0.81-1.65; P = 0.417) and CV events (HR 0.98; 95% CI 0.83-1.16; P = 0.817) between men and women after 1 year. Among the patients with HFmrEF, men had a higher 90-day risk of all-cause mortality than women after hospital discharge, and this risk disappeared after 1 year.Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT05240118 (ESC Heart Failure. (2022). doi: https://doi.org/10.1002/ehf2.14044 ).
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted a cohort in Heart failure with mildly reduced left ventricular ejection fraction (HFmrEF) (n=1,691). Male sex vs. Female sex was evaluated on 90-day all-cause mortality (HR 1.88, 95% CI 1.03-3.46, p=0.041). Male sex was associated with an 88% higher risk of 90-day all-cause mortality compared to female sex in patients with heart failure and mildly reduced ejection fraction (HR 1.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: